Segmentation by type classifies toxicology testing services into In‑vitro, In‑vivo, and Computational approaches, each with distinct methodological sub‑categories. In‑vitro testing, which includes cell‑based assays, organ‑on‑a‑chip platforms, and high‑throughput screening, is expanding rapidly due to ethical pressures and regulatory acceptance, capturing a growing share of the market. In‑vivo testing remains essential for systemic toxicity endpoints and comprises acute, sub‑chronic, chronic, reproductive, and developmental studies; it sustains a stable revenue base despite ongoing calls for reduction. Computational testing—encompassing quantitative structure‑activity relationship (QSAR) modeling, read‑across, and physiologically based pharmacokinetic (PBPK) simulations—offers cost‑effective risk assessment and is increasingly integrated with other methods to form integrated testing strategies. The interplay of these types determines the overall market composition, as firms balance scientific rigor, regulatory compliance, and cost efficiency when selecting the appropriate testing portfolio.